2. Others
  3. Biochemical Assay Reagents
  4. Sodium phosphate dibasic, meets analytical specification of Ph. Eur. BP USP FCC E339

Sodium phosphate dibasic, meets analytical specification of Ph. Eur. BP USP FCC E339  (Synonyms: Disodium hydrogen phosphate, meets analytical specification of Ph. Eur. BP USP FCC E339)

Cat. No.: HY-Y0308D
Handling Instructions Technical Support

Sodium phosphate dibasic (Disodium hydrogen phosphate), meets analytical specification of Ph. Eur. BP USP FCC E339 is an inorganic dibasic phosphate that functions as an electrolyte supplement, a buffer carrier for injectable drugs, while also exhibiting nephrotoxicity. Sodium phosphate dibasic, meets analytical specification of Ph. Eur. BP USP FCC E339 induces extensive nephrotic syndrome-like changes, including systemic symptoms such as persistent proteinuria, lipemia, hypercholesterolemia, and anemia, and causes severe renal pathological alterations such as renal enlargement, glomerular calcification, podocyte injury, and tubulointerstitial lesions. Sodium phosphate dibasic, meets analytical specification of Ph. Eur. BP USP FCC E339 has the ability to induce phosphate-induced nephropathy and glomerular calcification, and can be widely used in studies on nephrotic syndrome and related renal pathological mechanisms.

For research use only. We do not sell to patients.

Sodium phosphate dibasic, meets analytical specification of Ph. Eur. BP USP FCC E339

Sodium phosphate dibasic, meets analytical specification of Ph. Eur. BP USP FCC E339 Chemical Structure

CAS No. : 7558-79-4

Size Stock
50 mg   Get quote  
100 mg   Get quote  
250 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Other In-stock Forms of Sodium phosphate dibasic, meets analytical specification of Ph. Eur. BP USP FCC E339:

Sodium phosphate dibasic, meets analytical specification of Ph. Eur. BP USP FCC E339 Related Antibodies

Top Publications Citing Use of Products

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Sodium phosphate dibasic (Disodium hydrogen phosphate), meets analytical specification of Ph. Eur. BP USP FCC E339 is an inorganic dibasic phosphate that functions as an electrolyte supplement, a buffer carrier for injectable drugs, while also exhibiting nephrotoxicity. Sodium phosphate dibasic, meets analytical specification of Ph. Eur. BP USP FCC E339 induces extensive nephrotic syndrome-like changes, including systemic symptoms such as persistent proteinuria, lipemia, hypercholesterolemia, and anemia, and causes severe renal pathological alterations such as renal enlargement, glomerular calcification, podocyte injury, and tubulointerstitial lesions. Sodium phosphate dibasic, meets analytical specification of Ph. Eur. BP USP FCC E339 has the ability to induce phosphate-induced nephropathy and glomerular calcification, and can be widely used in studies on nephrotic syndrome and related renal pathological mechanisms[1][2][3].

In Vivo

Sodium phosphate dibasic, meets analytical specification of Ph. Eur. BP USP FCC E339 (409.6 mg/kg/day; tail vein; once daily; 14 or 28 days) induces irreversible, progressive nephrotic syndrome in male Sprague-Dawley rats, characterized by persistent proteinuria, a 60% reduction in albumin/globulin ratio, up to 6.4-fold elevated cholesterol, up to 4.8-fold elevated triglycerides, up to 1.4-fold elevated platelets, up to 2.3-fold elevated fibrinogen, a slight decrease in serum Ca2+ only in the 28-day group, and severe renal morphological damage that worsens during withdrawal[1].
Sodium phosphate dibasic, meets analytical specification of Ph. Eur. BP USP FCC E339 (360 mM (409.6 mg/kg/day); i.v.; once daily; single dose, 3 consecutive days, or 8 consecutive days) induces progressive glomerular damage including proteinuria, podocyte injury, and calcification in male Sprague-Dawley rats, with all treated rats showing moderate to severe proteinuria by day 8 and glomerular calcification evident after 8 days of dosing[2].
Sodium phosphate dibasic (1-408 mg/kg; i.v.; once daily; 14 days) induces dose-dependent glomerular calcification, epithelial degeneration, and proteinuria in male Sprague-Dawley rats at 284 mg/kg and 408 mg/kg, with no adverse effects observed at 1 mg/kg or 28 mg/kg[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Jcl:SD (male, 5 weeks old at study start, nephrotic syndrome induced by daily tail-vein injections of dibasic sodium phosphate)[1]
Dosage: 360 mM (409.6 mg/kg/day) (14-day treatment + 14-day withdrawal; 28-day treatment)
Administration: tail vein; once daily; 14 days followed by 14-day withdrawal; once daily; 28 days
Result: Detected persistent proteinuria first on day 3, with all treated rats showing moderate to severe proteinuria from day 8 onward; proteinuria persisted without remission after the 14-day withdrawal period.
Increased total cholesterol up to 6.4-fold in the 28-day group and 5.3-fold in the withdrawal group.
Increased triglycerides up to 4.8-fold in the 28-day group.
Reduced albumin/globulin ratio by 60% in the 28-day group and 57% in the withdrawal group.
Decreased red blood cell count, hematocrit, and hemoglobin levels to 70-80% of control values.
Increased platelet count up to 1.4-fold.
Increased fibrinogen levels up to 2.3-fold.
Kept serum inorganic phosphorus levels unchanged relative to controls.
Caused a slight decrease in serum calcium only in the 28-day group, with no change in the withdrawal group.
Increased absolute kidney weight to 1.71-fold of control in the 28-day group and 1.31-fold of control in the withdrawal group; kidneys appeared pale, markedly enlarged, and had a rough surface.
Induced glomerular lesions including widespread mineralization, capillary dilatation, partial adhesion of glomerular tufts to Bowman’s capsule, mesangiolysis, and occasional mesangial sclerosis.
Induced tubulointerstitial lesions including tubular regeneration, dilatation, protein casts, basement membrane mineralization, focal interstitial inflammation, and fibrosis; lesions worsened during the withdrawal period despite no further treatment.
Revealed glomerular basement membrane thickening, podocyte foot process effacement, increased podocyte microvilli, and lamellar structure deposits in glomerular tissues via electron microscopy.
Showed significant reduction in podoplanin-positive podocytes and increased desmin expression in podocytes of treated rats via immunohistochemistry.
Observed spleen enlargement and extramedullary hematopoiesis in the 28-day group.
Detected focal mineralization in lung alveolar septa, heart small artery walls, aortic arch endothelium, and thyroid/parathyroid interstitium in the 28-day group, and in thyroid glands in the withdrawal group.
Animal Model: Jcl:SD (male, 6 weeks of age)[2]
Dosage: 360 mM (409.6 mg/kg/day)
Administration: i.v.; once daily; single dose, 3 consecutive days, or 8 consecutive days
Result: Detected no increased urinary protein after single dosing.
Observed increased urinary protein (100 mg/dl/4 hr, 2+) in 2/10 treated rats on day 3.
Found almost all treated rats had urinary protein levels of 100-1000 mg/dl/4 hr (2+ to 4+) on day 5.
Showed all treated rats had moderate to severe proteinuria by day 8.
Detected no glomerular lesions after single dosing.
Observed minimal/focal calcium deposition in parietal epithelial cells in 2/5 rats after 3 days of dosing.
Identified focal calcification of glomerular basement membrane (GBM) and mesangium, plus minimal to mild calcium deposition in parietal epithelial cells, accompanied by hypertrophy and increased mitotic figures in parietal epithelial cells after 8 days of dosing.
Observed small vacuoles scattered in Bowman’s space, small vacuoles in podocyte cytoplasm, and partially electron-dense, irregularly thickened capillary endothelium after single dosing.
Found low-density lamellar structures in Bowman’s space, GBM, and mesangial matrix, podocyte hypertrophy, podocyte foot process effacement, increased microvilli, and debris-filled Bowman’s space after 3 days of dosing.
Detected severe podocyte degeneration, accreted lamellar structures in parietal epithelia, podocytes, and GBM, and thickened GBM after 8 days of dosing.
Observed increased desmin expression in glomerular tufts, decreased podoplanin expression in podocytes and parietal epithelial cells, and a tendency toward increased numbers of PCNA-positive podocytes and parietal epithelial cells on day 9.
Molecular Weight

141.96

Formula

Na2HPO4
CAS No.
SMILES

[Na2HPO4]
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Sodium phosphate dibasic, meets analytical specification of Ph. Eur. BP USP FCC E339 Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Sodium phosphate dibasic, meets analytical specification of Ph. Eur. BP USP FCC E3397558-79-4Disodium hydrogen phosphate, meets analytical specification of Ph. Eur. BP USP FCC E339Biochemical Assay Reagentsphosphate-induced nephropathyproteinuriamale Sprague-Dawley ratsratsglomerular calcificationmesangiolysisnephrotic syndromecapillary endothelium thickeningtubulointerstitial lesionspodocyte damageInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Sodium phosphate dibasic, meets analytical specification of Ph. Eur. BP USP FCC E339
Cat. No.:
HY-Y0308D
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.